ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
IQVIA Holdings Inc

IQVIA Holdings Inc (IQV)

209.97
0.81
( 0.39% )
Updated: 14:39:15

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
209.97
Bid
-
Ask
-
Volume
1,583,801
205.09 Day's Range 210.67
190.20 52 Week Range 261.73
Market Cap
Previous Close
209.16
Open
205.09
Last Trade
3
@
210.0389
Last Trade Time
14:39:22
Financial Volume
US$ 330,384,547
VWAP
208.6023
Average Volume (3m)
1,079,814
Shares Outstanding
182,300,000
Dividend Yield
-
PE Ratio
28.27
Earnings Per Share (EPS)
7.45
Revenue
14.98B
Net Profit
1.36B

About IQVIA Holdings Inc

IQVIA Holdings Inc is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceuti... IQVIA Holdings Inc is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The Technology & Analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business. Show more

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
IQVIA Holdings Inc is listed in the Coml Physical, Biologcl Resh sector of the New York Stock Exchange with ticker IQV. The last closing price for IQVIA was US$209.16. Over the last year, IQVIA shares have traded in a share price range of US$ 190.20 to US$ 261.73.

IQVIA currently has 182,300,000 shares outstanding. The market capitalization of IQVIA is US$38.13 billion. IQVIA has a price to earnings ratio (PE ratio) of 28.27.

IQV Latest News

IQVIA Reports Third-Quarter 2024 Results and Announces Investor Day

Revenue of $3,896 million GAAP Net Income of $285 million, Adjusted EBITDA of $939 million GAAP Diluted Earnings per Share of $1.55, Adjusted Diluted Earnings per Share of $2.84 R&D...

IQVIA to Announce Third-Quarter 2024 Results on October 31, 2024

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31, 2024. The IQVIA management team will also host a...

IQVIA Announces IQVIA AI Assistant, Powered by IQVIA Healthcare-grade AI™

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today introduces IQVIA...

IQVIA AI Solution Receives 2024 Frost & Sullivan Global Customer Value Leadership Award

Award Recognizes Leadership in AI Regulatory and Quality Solutions for Healthcare IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research...

Signant Health expands availability of its eClinical solutions by joining IQVIA One Home for Sites initiative

Signant Health expands availability of its eClinical solutions by joining IQVIA One Home for Sites initiative PR Newswire PHILADELPHIA, Sept. 4, 2024 PHILADELPHIA, Sept. 4, 2024 /PRNewswire/...

IQVIA CFO Ron Bruehlman to Speak at the Morgan Stanley Annual Global Healthcare Conference on September 4, 2024

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Morgan Stanley Annual Healthcare Conference in...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-7.48-3.43987123477217.45219.1200.35531817527211.23343692CS
4-17.27-7.59989438479227.24237.335200.35531178363220.62392451CS
12-27.33-11.5170670038237.3252.88200.35531079814233.32064786CS
26-15-6.66755567409224.97252.88200.35531154605228.00794515CS
5213.36.76259724411196.67261.73190.21086164227.23013389CS
156-44.65-17.5359359045254.62285.61165.751068835219.46328581CS
26062.2142.1020573904147.76285.6181.791096091198.91208146CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CCChemours Company
US$ 20.65
(15.88%)
4.35M
NOVASunnova Energy International Inc
US$ 6.35
(10.82%)
8.78M
BIO.BBio Rad Laboratories Inc
US$ 370.00
(10.50%)
4
HYAC.UHaymaker Acquisition Corp 4
US$ 11.89
(9.99%)
5
BFAC.UBattery Future Acquisition Corp
US$ 12.40
(9.93%)
1
KUKEKuke Music Holding Limited
US$ 0.3801
(-36.38%)
2.12M
PACSPACS Group Inc
US$ 29.84
(-30.51%)
12.03M
HBBHamilton Beach Brands Holding Company
US$ 20.72
(-21.93%)
214.36k
VATEINNOVATE Corp
US$ 5.08
(-14.19%)
125.22k
DOCNDigitalOcean Holdings Inc
US$ 35.46
(-13.15%)
2.77M
PLTRPalantir Technologies Inc
US$ 41.3001
(-1.48%)
43.63M
FFord Motor Company
US$ 10.355
(1.32%)
42.7M
NIONIO Inc
US$ 5.175
(1.47%)
32.89M
PFEPfizer Inc
US$ 27.786
(-1.08%)
27.22M
ITUBItau Unibanco Holding SA
US$ 6.095
(2.61%)
23.81M

IQV Discussion

View Posts
scoobey-do scoobey-do 4 years ago
IQVIA Announces Pricing of Offering of Senior Notes

February 17, 2021

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C. – IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of €1,450,000,000 in aggregate principal amount of senior notes, consisting of €550,000,000 in aggregate principal amount of senior notes due 2026 (the “2026 Notes”) and €900,000,000 in aggregate principal amount of senior notes due 2029 (the “2029 Notes” and, together with the 2026 Notes, the “Notes”). The proceeds from the Notes offering will be used to redeem all of the Issuer’s outstanding 3.250% senior notes due 2025, including the payment of premiums in respect thereof, and to pay fees and expenses related to the Notes offering.

The 2026 Notes will bear interest at a rate of 1.750% per annum and will pay interest semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2021. The 2026 Notes will mature on March 15, 2026, unless earlier repurchased or redeemed in accordance with their terms. The 2029 Notes will bear interest at a rate of 2.250% per annum and will pay interest semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2021. The 2029 Notes will mature on March 15, 2029, unless earlier repurchased or redeemed in accordance with their terms. The issuance of the Notes is expected to occur on or about March 3, 2021, subject to the satisfaction of customary closing conditions.

Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering and potential changes in market conditions that could cause actual results to differ materially.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 70,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.

Contacts

IQVIA Holdings Inc.

Investor Relations:

Andrew Markwick, 973-257-7144

andrew.markwick@iqvia.com

https://www.otcmarkets.com/filing/html?id=14719842&guid=VrOaUF9quVaTeth#D133451DEX991_HTM
👍️0
JFBroderick JFBroderick 6 years ago
$200 stock in the making.
👍️0